Keywords: Ligand Pharma, Chiva Pharma, Fablyn, Osteoporosis, Global license
Ligand in deal with Chiva for global rights to Fablyn
Article | 12 October 2011
In a second deal with the company, Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a global licensing agreement with Chiva ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
